Table 2.
LCBF, LCMRglc, and LCMRglc:LCBF ROI Data from the Ipsilateral Hemisphere
| Core | Marg | CA1 | CA3 | DG | Thal | Cing | CC | EC | IC | |
|---|---|---|---|---|---|---|---|---|---|---|
| LCBF (mL/100 g−1 min−1) | ||||||||||
| Sham | 85.6±1.3 | 112.7±2.4 | 98.6±3.6 | 102.4±2.5 | 115.4±1.9 | 147.4±2.2 | 87.1±2.0 | 54.5±2.9 | 73.1±0.6 | 81.9±1.4 |
| Untreated | 26.0±3.0 | 47.0±0.9 | 50.0±1.6 | 55.6±1.5 | 59.4±1.8 | 71.4±3.0 | 29.6±1.3 | 39.4±2.7 | 61.8±0.7 | 70.8±0.8 |
| ACZ | 38.8±3.6 | *116.8±4.9 | 101.6±2.6 | 96.8±3.4 | *129.6±2.6 | *170.4±3.2 | 62.2±2.7 | *61.2±2.9 | 101.8±1.6 | *106.0±2.4 |
| LCMRglc (μmol/100 g−1 min−1) | ||||||||||
| Sham | 74.8±3.2 | 65.3±5.9 | 63.8±8.7 | 63.0±6.2 | 60.7±4.7 | 83.9±5.5 | 60.0±4.8 | 49.0±7.1 | 63.4±1.4 | 47.2±3.4 |
| Untreated | 37.2±7.3 | 85.6±2.3 | 77.1±3.8 | 79.5±3.6 | 73.0±4.4 | 75.9±7.4 | 64.0±3.3 | 67.8±6.5 | 59.2±1.8 | 55.1±2.0 |
| ACZ | 38.8±8.9 | 72.8±11.9 | 59.2±6.3 | 60.3±8.4 | 59.7±6.3 | 65.6±7.8 | 55.1±6.7 | 48.8±7.1 | 48.7±3.9 | 50.1±5.9 |
| LCMRglc:LCBF (μmol/mL−1) | ||||||||||
| Sham | 1.0±0.04 | 0.7±0.08 | 0.6±0.08 | 0.5±0.04 | 0.5±0.04 | 0.4±0.12 | 0.8±0.08 | 0.8±0.16 | 0.7±0.04 | 0.5±0.04 |
| Untreated | 1.5±0.37 | 2.6±1.06 | 1.5±0.20 | 1.8±0.45 | 1.7±0.33 | 1.3±0.20 | 2.5±0.41 | 1.7±0.16 | 1.1±0.12 | 0.6±0.08 |
| ACZ | 1.1±0.33 | **0.7±0.16 | **0.6±0.08 | 0.8±0.20 | *0.5±0.04 | *0.5±0.12 | *1.0±0.16 | *0.9±0.20 | *0.6±0.08 | 0.5±0.04 |
Values are mean±standard error of the mean.
*
p<0.05; **p<0.01. ROI, region-of-interest; LCBF, local cerebral blood flow; LCMRglc, local metabolic rate for glucose; LCMRglc:LCBF, metabolism:flow ratio; ACZ, acetazolamide; DG, dentate gyrus; Thal, thalamus; Cing, cingulum; CC, corpus callosum; EC, external capsule; IC, internal capsule.